Search results for " Mab"
Article
Cost Considerations Drive Lean Technology in Biopharmaceutical Manufacturing
As of February 2017, FDA lists 68 approved mAbs, and approvals have been increasing each year since the late 1990s (3). mAbs are comprised of several domains that contribute to their function. The Fab…
Article
Ligand-Binding Assays and the Determination of Biosimilarity
In addition, for mAbs, ligand-binding assays do provide a valuable assessment of biosimilarity and should be included, orthogonally, with cell-based functionality assessments.
Just one part of the…
Article
Single-Domain Antibodies for Brain Targeting
With 25 mAb products on the market and more than 100 undergoing clinical trials (1-3), it is evident that engineered antibodies have come of age as biopharmaceuticals (4).
Intact antibodies (immun…
Article
Digitalization: The Route to Biopharma 4.0
High-Throughput Screening Techniques for Rapid PEG-Based Precipitation of IgG4 mAb from Clarified Cell Culture Supernatant. Biotechnol. Prog. 2010, 26, 697–705.
3. Dörr, M; Fibinger M. P. C.; La…
Article
As the therapeutic pipeline diversifies, chromatography toolboxes are expanding.
For traditional mAbs, protein A chromatography is used to capture antibodies. Depending on the structure of the target antibody and the impurity profile, other affinities, like protein L or variants o…
Article
Top Process Development Trends for 2021 and a Look into 2022
In the 1980s and 1990s, mAb titers were only 0.5 g/L. From the 1990s onward, the average mAb titers have increased a full order of magnitude; today, it’s common to reach 3–10 g/liter as a result of hi…
Article
Updating Viral Clearance for New Biologic Modalities
Guidance is needed
Compounding all these challenges is the fact that published regulatory guidances have been based on traditional biologics, such as mAbs and related Protein A binders, says Berri…
Article
Process Development: 2020 Reflections and 2021 Possibilities
On the note of mAbs, another area of interest in 2020 was strategies to improve the mAb manufacturing process and streamline overall bioprocessing operations. mAb manufacturing productivity can be gre…
Article
Reimagining Affordable Biosimilars
A typical study for complex biologics, such as mAbs, includes the following components: assessment of acute toxicity (two-weeks to one month) via single- and multi-dose studies, including evaluation o…
Article
Flexible Facilities for Viral Vector Manufacturing
Increased biosafety requirement
Viral-vector manufacturing has some similarities to mAb manufacturing, but also some differences. “Compared to mAbs, viral vectors are much larger, more complex mol…